Evidence map›Paper›PMID 34107117›Full record

ArticleInternational journal of clinical practice2021

The boundaries between survival and nonsurvival at COVID-19: Experience of tertiary care pandemic hospital.

Yakup Arslan, Deniz Dogan, Nesrin Ocal, Alperen Koc, Tunahan Ayaz, Recep Ozkan, Fatma Yoruk, Meltem Nilsen Esmer, Sumeyye Kosger, Ekin Kadioglu and 9 more

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 2 countries.

Yakup ArslanDepartment of Chest Diseases, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-9079-1701
Deniz DoganDepartment of Chest Diseases, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0003-2596-3113
Nesrin OcalDepartment of Chest Diseases, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-3789-7769
Alperen KocDepartment of Chest Diseases, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0001-6292-2607
Tunahan AyazDepartment of Infectious Diseases and Clinical Microbiology, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-5110-8092
Recep OzkanDepartment of Underwater Medicine and Hyperbaric Medicine, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0001-7342-6473
Fatma YorukDepartment of Internal Medicine, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0003-4783-8284
Meltem Nilsen EsmerDepartment of Gynecology and Obstetrics, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0003-1198-3703
Sumeyye KosgerDepartment of Infectious Diseases and Clinical Microbiology, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0003-2838-8425
Ekin KadiogluDepartment of Internal Medicine, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-4870-1469
Umit SavasciDepartment of Infectious Diseases and Clinical Microbiology, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0003-3663-2053
Ferhat CuceDepartment of Radiology, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0003-1831-3868
Gonca FidanDepartment of Infectious Diseases and Clinical Microbiology, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-0972-4510
Gulden YilmazDepartment of Infectious Diseases and Clinical Microbiology, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-2186-492X
Neslihan Kayahan SatisDepartment of Internal Medicine, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-6802-7926
Sedat BilgeDepartment of Emergency Medicine, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0002-0669-2859
Serkan SenkalDepartment of Chest Diseases, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0001-8196-3834
Canturk TasciDepartment of Chest Diseases, Ankara Gulhane Training and Research Hospital, Health Sciences University, Ankara, Turkey.ORCID https://orcid.org/0000-0003-4596-5095
Hakan KayirDepartment of Biomedical Sciences, Ontario Veterinary College at University of Guelph, Guelph, ON, Canada.ORCID https://orcid.org/0000-0002-6423-4207
Sağlık Bilimleri Üniversitesi · TRMinistry of Health · TRUniversity of Guelph · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCoronavirus disease 2019 (COVID-19) is an emerging, fast-spreading, highly mortal and worldwide infectious disease. The pulmonary system was defined as the main target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the mortality concept of this disease presented with more severe and systemic disease. The present study investigated the relationship between the patient characteristics at the initial hospital administration and fatality in COVID-19 patients.

methodsIn this retrospective and comparative cohort study, all the 767 hospitalised COVID-19 patients, treated between 18 March and 15 May 2020 in the Covid Clinics of Gulhane Training and Research Hospital in Ankara, Turkey, were evaluated.

resultsThe fatality rate was significantly increased in patients with any comorbid disease except asthma. The initial laboratory test results indicated highly significant differences according to the patient's outcome. A multifactor logistic regression analysis was performed to calculate the adjusted odds ratios for predicting patient outcomes. Being older than 60 years increased the death risk with an adjusted OR of 7.2 (95% CI: 2.23-23.51; P = .001). The presence of a cancer and the extended duration of intensive care unit treatment were other significant risk factors for nonsurvival. Azithromycin treatment was determined as significantly reduced the death ratio in these patients (P = .002).

conclusionIt was revealed that being older than 60 years, presence of a cancer and extended duration of ICU treatment were the major risk factors for predicting fatality rate in hospitalised COVID-19 patients.

Indexed as

COVID-19PandemicsCohort StudiesHospitalizationHospital MortalityHospitalsHumansIntensive Care UnitsRetrospective StudiesSARS-CoV-2Tertiary Health Care

Identifiers

PMID34107117
PMCPMC8236934
OpenAlexW3169250998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.